Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Zydus Lifesciences LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:532321NSE Symbol: ZYDUSLIFEP/E(TTM):18.09
ISIN Demat:INE010B01027Div & Yield %:1.27EPS(TTM):47.96
Book Value(Rs):215.0764496Market Cap ( Cr.):87320.99Face Value(Rs):1
    Change Company 
Date Headline
13-Jan-26 Zydus Lifesciences’ US arm secures FDA nod for ZYCUBO in Pediatric Menkes Patients
13-Jan-26 Sentynl (Zydus Group) receives USFDA approval for ZYCUBO®
06-Jan-26 Zydus Lifesciences Ltd spurts 0.27%, up for fifth straight session
23-Dec-25 Zydus partners with Bioeq for licensing, supply and commercialization of Lucentis® in US market
19-Dec-25 Zydus signs agreement with Myriad Genetics
15-Dec-25 Sentynl announces USFDA Acceptance of CUTX-101 NDA resubmission
10-Dec-25 Zydus launches Zyrifa - a Denosumab biosimilar
10-Dec-25 Zydus Lifesciences gains after launching Denosumab Biosimilar
04-Dec-25 Zydus Lifesciences receives EIR for facility at Jarod, Vadodara
28-Nov-25 Zydus Life gets US FDA nod for generic version of antidiabetic combination drug Glyxambi
<< < 1 2 3 4   > >>